查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403498

2030 年内分泌检测市场预测：按检测类型、技术、最终用户和地区进行的全球分析

Endocrine Testing Market Forecasts to 2030 - Global Analysis By Test Type (Human Chorionic Gonadotropin Hormone Test, Prolactin Test, Progesterone Test and Other Test Types), Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球内分泌检测市场规模为 28 亿美元，预计在预测期内复合年增长率为 10.4%，到 2030 年将达到 55 亿美元。

内分泌测试评估人体内分泌系统中的荷尔蒙水平。透过测量血液、尿液和唾液样本中的荷尔蒙水平，此诊断程序有助于识别荷尔蒙失衡和疾病。甲状腺激素、皮质醇、胰岛素、睪固酮和雌激素等生殖激素都是经常检测的荷尔蒙。

根据世界卫生组织（WHO）2022年3月的数据，全球有6.5亿成年人、3.4亿青少年和3,900万名儿童患有肥胖症，而且这一数字仍在持续增长。

与生活方式相关的疾病增加

内分泌相关疾病的增加部分是由于生活方式的改变，例如久坐的生活方式和不健康的饮食习惯。人们越来越需要能够准确识别荷尔蒙失衡并提供此类疾病早期诊断的诊断测试。此外，内分泌检测市场受到医疗专业人员的推动，他们寻求尖端设备来解决诊断文明病的挑战，以及准确及时的激素评估以实现有效疾病治疗的需求。由于对性别的重视，预计会出现增长。

检体采集错误

正确的检体采集、储存和运输对于确保准确的荷尔蒙水平测量非常重要。检体处理不当、污染和运输延误等问题可能会损害检体的完整性并导致测试结果不准确。结果的差异也可能是由于使用不一致的资料收集方法的医疗保健环境的差异造成的。然而，为了保持内分泌检测的准确性和一致性，必须解决与此类检体相关的问题，并强调需要对医疗保健专业人员进行统一的程序和培训。我是。

伴同性诊断剂

伴同性诊断透过为内分泌疾病的个体化治疗提供量身定制的解决方案，为内分泌检测市场提供了独特的机会。透过识别特定的生物标记或遗传标记物，这些诊断可以帮助医疗专业人员为患者配对最合适的治疗方法。这种精确的方法可以最大限度地减少副作用，最大限度地提高治疗性介入，并改善内分泌检测的结果。此外，这种客製化方法将提高内分泌相关医疗保健的整体有效性和经济性，同时改善病患照护。

智慧财产权挑战

智慧财产权问题源自于新测试、生物标记和诊断技术的创建和应用。花钱进行研发的公司必须担心专利侵权，因为竞争对手可能会试图模仿或增强自己的测试方法。内分泌诊断的动态性质引起了对现有专利的范围和有效性的质疑，并引发了智慧财产权纠纷。

COVID-19 的影响：

内分泌检测市场受到了 COVID-19 大流行的严重影响。由于内分泌系统是受病毒影响的器官之一，因此越来越需要内分泌检测来评估感染者的荷尔蒙失衡和併发症。由于需要全面的诊断解决方案来了解病毒如何影响荷尔蒙水平，内分泌检测产业正在经历创新和研究的激增。由于重点在于内分泌疾病的诊断和治疗，儘管医疗保健系统受到干扰，但在这些困难时期，内分泌检测市场仍持续成长。

免疫测量领域预计将成为预测期内最大的领域

由于荷尔蒙和相关生物标记鑑定的高灵敏度和特异性，免疫测量领域正在经历显着的增长。内分泌疾病（包括糖尿病和甲状腺问题）的日益普及推动了对准确有效的诊断技术的需求。此外，自动化、新检测方法的开发和技术的发展也促进了这一领域的成长。

胰岛素检测领域预计在预测期内复合年增长率最高

预计胰岛素测试领域在预测期内复合年增长率最高。胰岛素检测的需求量很大，因为糖尿病管理很大程度上依赖监测胰岛素水平。该领域的发展也得益于测试技术的进步，包括更快、更准确的检测。胰岛素检测的采用也受到对个人化医疗和糖尿病早期检测的日益重视的影响。

比最大的地区

由于内分泌疾病盛行率不断上升、荷尔蒙健康意识不断增强以及医疗基础设施的进步，亚太地区所占份额最大。最新诊断技术的采用和医疗保健设施的扩张正在促进市场的成长。此外，不断增加的研发投入和政府的积极措施也进一步推动了市场的扩张。

复合年增长率最高的地区：

由于北美内分泌疾病盛行率不断上升以及公众对疾病早期检测的意识不断增强，该市场正在见证盈利增长。该地区高额的医疗保健支出和发达的医疗基础设施进一步推动了市场的成长。此外，生物技术和製药行业研发支出的增加正在推动内分泌检测技术的创新，进一步推动该地区的成长。

免费客製化服务：

订阅此报告的客户将收到以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球内分泌检测市场：依检测类型

  • 人类绒毛膜促性腺激素分泌检测
  • 催乳素测试
  • 黄体酮测试
  • 胰岛素测试
  • 甲状腺刺激素测试
  • 黄体激素测试
  • 硫酸磊晶试验
  • 雌二醇试验
  • 皮质醇测试
  • 睪酮测试
  • 滤泡刺激素测试
  • 其他测试类型

第六章全球内分泌检测市场：依技术分类

  • 基于核酸的
  • 质谱
  • 层析法
  • 免疫检测
  • 其他技术

第七章全球内分泌检测市场：依最终用户分类

  • 临床实验室
  • 诊断中心
  • 医院
  • 其他最终用户

第八章全球内分泌检测市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • AB Sciex
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Beckman Coulter, Inc.
  • Biomedical Technologies Limited
  • BioMerieux SA
  • Bio Rad Laboratories, Inc.
  • Danaher Corporation
  • DH Tech. Dev. Pte. Ltd.
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • Laboratory Corporation of America Holdings
  • Ortho Clinical Diagnostics
  • Qiagen NV
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
Product Code: SMRC24723

According to Stratistics MRC, the Global Endocrine Testing Market is accounted for $2.8 billion in 2023 and is expected to reach $5.5 billion by 2030 growing at a CAGR of 10.4% during the forecast period. Endocrine testing involves the assessment of hormone levels in the body's endocrine system, which regulates various physiological functions. By determining the hormone concentrations in blood, urine, or saliva samples, this diagnostic procedure aids in the identification of hormonal imbalances or disorders. Thyroid hormones, cortisol, insulin, and reproductive hormones like testosterone and estrogen are among the hormones that are frequently tested.

According to the World Health Organization (WHO) in March 2022, 650 million adults, 340 million teenagers, and 39 million children are obese around the world and the number is still rising.

Market Dynamics:

Driver:

Rise in disorders associated with lifestyle

The increase in the endocrine related disorders is partly attributed to alterations in lifestyle patterns, like sedentary lifestyle and unhealthy eating habits. The need for diagnostic tests that can precisely identify hormonal imbalances and offer early diagnosis of such conditions has increased. Additionally, the market for endocrine testing is expected to grow as medical professionals look for cutting-edge instruments to handle the difficulties in diagnosing lifestyle-related illnesses, stressing the need for accurate and timely hormone evaluations for efficient illness treatment.

Restraint:

Errors in specimen collection

Appropriate specimen collection, storage, and transportation are critical to guaranteeing accurate hormone level measurements. Problems like incorrect sample handling, contamination, or transportation delays can damage the samples' integrity and produce inaccurate test results. Variability in outcomes may also be caused by different healthcare settings using inconsistent methods for data collection. However, it is imperative that these sample-related issues are resolved in order to preserve the accuracy and consistency of endocrine tests, underscoring the necessity of uniform procedures and training for healthcare personnel.

Opportunity:

Companion diagnostics

Companion diagnostics present a unique opportunity in the endocrine testing market by offering tailored solutions for personalized treatment in endocrine disorders. By identifying particular biomarkers or genetic markers, these diagnostics assist medical professionals in matching patients with the most appropriate treatments. This precision approach minimizes side effects, maximizes therapeutic interventions, and improves treatment outcomes in endocrine testing. Moreover, this customized approach enhances patient care while also adding to the general efficacy and affordability of endocrine-related healthcare.

Threat:

Intellectual property challenges

Intellectual property issues are brought about by the creation and application of novel testing techniques, biomarkers, and diagnostic technologies. Businesses that spend money on R&D have to worry about patent infringement because rivals might try to copy or enhance proprietary testing methods. The dynamic nature of endocrine diagnostics gives rise to inquiries concerning the extent and legitimacy of existing patents, thereby engendering conflicts concerning intellectual property rights.

COVID-19 Impact:

The endocrine testing market has been greatly affected by the COVID-19 pandemic. The endocrine system is one of the organs that the virus can affect, so there is a greater need for endocrine tests to evaluate hormonal imbalances and complications in infected individuals. The endocrine testing industry has seen a surge in innovation and research due to the need for comprehensive diagnostic solutions to comprehend the virus's impact on hormone levels. The focus on diagnosing and treating endocrine disorders has kept the endocrine testing market growing during these difficult times, despite disruptions in the healthcare system.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment has grown substantially because of its high sensitivity and specificity in identifying hormones and associated biomarkers. The need for precise and effective diagnostic techniques has been fueled by the rising incidence of endocrine disorders, including diabetes and thyroid issues. Furthermore, automation, the creation of new assays, and technological developments has all contributed to this segment's growth.

The insulin test segment is expected to have the highest CAGR during the forecast period

Insulin test segment is expected to have the highest CAGR during the forecast period. Insulin tests are in high demand because diabetes management greatly depends on insulin level monitoring. The sector's growth has also been aided by developments in testing technologies, such as faster and more accurate assays. Insulin test adoption has also been influenced by the growing emphasis on personalized medicine and the early detection of diabetes.

Region with largest share:

Asia Pacific region dominated the largest share due to the increasing prevalence of endocrine disorders, rising awareness about hormonal health, and advancements in healthcare infrastructure. The adoption of modern diagnostic technologies and the expansion of healthcare facilities contribute to the market's upward trajectory. Additionally, heightened investments in research and development, coupled with proactive government initiatives, further fuel the market's expansion.

Region with highest CAGR:

The market has grown profitably in North America due to rising incidence of endocrine disorders and increased public awareness of early disease detection. The region's high healthcare spending and well-established healthcare infrastructure have further stimulated market growth. Furthermore, increased R&D spending in the biotechnology and pharmaceutical industries has sparked innovation in endocrine testing techniques, which has further fuelled the regional growth.

Key players in the market:

Some of the key players in Endocrine Testing market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter, Inc., Biomedical Technologies Limited, BioMerieux SA, Bio Rad Laboratories, Inc. , Danaher Corporation, DH Tech. Dev. Pte. Ltd., DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Laboratory Corporation of America Holdings, Ortho Clinical Diagnostics, Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc, a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In May 2023, Hologic Inc., a global leader in women's health, announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Test Types Covered:

  • Human Chorionic Gonadotropin Hormone Test
  • Prolactin Test
  • Progesterone Test
  • Insulin Test
  • Thyroid Stimulating Hormone Test
  • Luteinizing Hormone Test
  • Dehydroepiandrosterone Sulfate Test
  • Estradiol Test
  • Cortisol Test
  • Testosterone Test
  • Follicle Stimulating Hormone Test
  • Other Test Types

Technologies Covered:

  • Nucleic Acid Based
  • Mass Spectroscopy
  • Chromatography
  • Immunoassay
  • Other Technologies

End Users Covered:

  • Clinical Laboratories
  • Diagnostic Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Endocrine Testing Market, By Test Type

  • 5.1 Introduction
  • 5.2 Human Chorionic Gonadotropin Hormone Test
  • 5.3 Prolactin Test
  • 5.4 Progesterone Test
  • 5.5 Insulin Test
  • 5.6 Thyroid Stimulating Hormone Test
  • 5.7 Luteinizing Hormone Test
  • 5.8 Dehydroepiandrosterone Sulfate Test
  • 5.9 Estradiol Test
  • 5.10 Cortisol Test
  • 5.11 Testosterone Test
  • 5.12 Follicle Stimulating Hormone Test
  • 5.13 Other Test Types

6 Global Endocrine Testing Market, By Technology

  • 6.1 Introduction
  • 6.2 Nucleic Acid Based
  • 6.3 Mass Spectroscopy
  • 6.4 Chromatography
  • 6.5 Immunoassay
  • 6.6 Other Technologies

7 Global Endocrine Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Clinical Laboratories
  • 7.3 Diagnostic Centers
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Endocrine Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AB Sciex
  • 10.2 Abbott Laboratories
  • 10.3 Agilent Technologies Inc.
  • 10.4 Beckman Coulter, Inc.
  • 10.5 Biomedical Technologies Limited
  • 10.6 BioMerieux SA
  • 10.7 Bio Rad Laboratories, Inc.
  • 10.8 Danaher Corporation
  • 10.9 DH Tech. Dev. Pte. Ltd.
  • 10.10 DiaSorin SpA
  • 10.11 F. Hoffmann-La Roche Ltd
  • 10.12 Hologic Inc.
  • 10.13 Laboratory Corporation of America Holdings
  • 10.14 Ortho Clinical Diagnostics
  • 10.15 Qiagen N.V.
  • 10.16 Quest Diagnostics
  • 10.17 Siemens Healthineers AG
  • 10.18 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Endocrine Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 3 Global Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
  • Table 4 Global Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
  • Table 5 Global Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
  • Table 6 Global Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
  • Table 7 Global Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
  • Table 8 Global Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
  • Table 9 Global Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
  • Table 10 Global Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
  • Table 11 Global Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
  • Table 12 Global Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
  • Table 13 Global Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
  • Table 14 Global Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 15 Global Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 16 Global Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
  • Table 17 Global Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 18 Global Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 19 Global Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 20 Global Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 21 Global Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 23 Global Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 24 Global Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 25 Global Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 28 North America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
  • Table 29 North America Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
  • Table 30 North America Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
  • Table 31 North America Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
  • Table 32 North America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
  • Table 33 North America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
  • Table 34 North America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
  • Table 35 North America Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
  • Table 36 North America Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
  • Table 37 North America Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
  • Table 38 North America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
  • Table 39 North America Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 40 North America Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 41 North America Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
  • Table 42 North America Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 43 North America Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 44 North America Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 45 North America Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 46 North America Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 47 North America Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 48 North America Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 49 North America Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 50 North America Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 53 Europe Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
  • Table 54 Europe Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
  • Table 55 Europe Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
  • Table 56 Europe Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
  • Table 57 Europe Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
  • Table 58 Europe Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
  • Table 59 Europe Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
  • Table 60 Europe Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
  • Table 61 Europe Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
  • Table 62 Europe Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
  • Table 63 Europe Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
  • Table 64 Europe Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 65 Europe Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 66 Europe Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
  • Table 67 Europe Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 68 Europe Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 69 Europe Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 70 Europe Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 71 Europe Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 72 Europe Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 73 Europe Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 74 Europe Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 75 Europe Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 78 Asia Pacific Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
  • Table 79 Asia Pacific Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
  • Table 80 Asia Pacific Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
  • Table 81 Asia Pacific Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
  • Table 82 Asia Pacific Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
  • Table 83 Asia Pacific Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
  • Table 84 Asia Pacific Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
  • Table 85 Asia Pacific Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
  • Table 86 Asia Pacific Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
  • Table 87 Asia Pacific Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
  • Table 88 Asia Pacific Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
  • Table 89 Asia Pacific Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 90 Asia Pacific Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 91 Asia Pacific Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
  • Table 92 Asia Pacific Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 93 Asia Pacific Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 94 Asia Pacific Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 95 Asia Pacific Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 96 Asia Pacific Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 Asia Pacific Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 98 Asia Pacific Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 99 Asia Pacific Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 100 Asia Pacific Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 103 South America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
  • Table 104 South America Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
  • Table 105 South America Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
  • Table 106 South America Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
  • Table 107 South America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
  • Table 108 South America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
  • Table 109 South America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
  • Table 110 South America Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
  • Table 111 South America Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
  • Table 112 South America Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
  • Table 113 South America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
  • Table 114 South America Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 115 South America Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 116 South America Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
  • Table 117 South America Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 118 South America Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 119 South America Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 120 South America Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 121 South America Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 122 South America Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 123 South America Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 124 South America Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 125 South America Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 128 Middle East & Africa Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
  • Table 129 Middle East & Africa Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
  • Table 130 Middle East & Africa Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
  • Table 131 Middle East & Africa Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
  • Table 132 Middle East & Africa Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
  • Table 133 Middle East & Africa Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
  • Table 134 Middle East & Africa Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
  • Table 135 Middle East & Africa Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
  • Table 136 Middle East & Africa Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
  • Table 137 Middle East & Africa Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
  • Table 138 Middle East & Africa Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
  • Table 139 Middle East & Africa Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 140 Middle East & Africa Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 141 Middle East & Africa Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
  • Table 142 Middle East & Africa Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 143 Middle East & Africa Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 144 Middle East & Africa Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 145 Middle East & Africa Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 146 Middle East & Africa Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 147 Middle East & Africa Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 148 Middle East & Africa Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 149 Middle East & Africa Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 150 Middle East & Africa Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)